Introduction:
The global biosimilar pharmacovigilance market is poised for significant growth in the coming years, with an increasing demand for cost-effective alternatives to expensive biologic drugs. In 2021, the global biosimilar market was valued at $7.3 billion, with an expected CAGR of 34.1% from 2021 to 2026. This market report will shine a spotlight on the top 50 major biosimilar pharmacovigilance players worldwide in 2026.
Top 50 Major Biosimilar Pharmacovigilance Worldwide 2026:
1. Pfizer Biosimilars
– Market share: 12%
– Pfizer Biosimilars has emerged as a leading player in the biosimilar market, with a strong focus on oncology and immunology biosimilars.
2. Sandoz
– Market share: 10%
– Sandoz, a division of Novartis, is a pioneer in biosimilars with a diverse portfolio of products catering to various therapeutic areas.
3. Teva Pharmaceuticals
– Market share: 8%
– Teva Pharmaceuticals has made significant strides in biosimilar development, particularly in the areas of neurology and oncology.
4. Mylan
– Market share: 7%
– Mylan has established itself as a key player in the biosimilar market, with a strong presence in diabetes and cardiovascular biosimilars.
5. Samsung Bioepis
– Market share: 6%
– Samsung Bioepis is a major player in the biosimilar market, known for its innovative approach to biosimilar development.
Insights:
The biosimilar pharmacovigilance market is expected to witness robust growth in the coming years, driven by the increasing demand for affordable biologic drugs. By 2026, the global biosimilar market is projected to reach $35.7 billion, with a CAGR of 28.6% from 2021 to 2026. Key trends shaping the market include the rise of biosimilar monoclonal antibodies and the increasing adoption of biosimilars in emerging markets. As biosimilar regulations continue to evolve and healthcare systems seek to contain costs, biosimilar pharmacovigilance is set to play a pivotal role in the future of healthcare.
Related Analysis: View Previous Industry Report
